Applications are now invited for appointment as Post-doctoral Fellows (several posts) (Ref.:CVVT/2021/08), to commence as soon as possible, for two to three years contract basis with the possibility of renewal subject to satisfactory performance and mutual agreement.
Applicants should possess a Ph.D. degree in microbiology, immunology or other relevant disciplines. Research experience in vaccines or therapeutics development would be an advantage.They should have a good command of written and spoken English, strong communication skills, and the ability to work independently and collaboratively in a multi-disciplinary team. They should also be self-motivated, organized, detail-minded and hardworking.
The appointee will be involved in projects focusing emerging infectious diseases. Extensive experience on cell and molecular biology techniques, and/or immunological assays is preferred.
Both fresh Ph.D. graduates and experienced postdoctoral researchers are welcome to apply.
A highly competitive salary commensurate with qualifications and experience will be offered, in addition to annual leave and medical benefits.
Applicants should submit their up-to-date C.V. and research publication list, quoting the job reference number, with information of current/expected remuneration and availability. Review of applications will commence as soon as possible and until the posts are filled, whichever is earlier.The information provided will be kept confidential and only be used for those purposes relating to your application. We are an equal opportunities employer and welcomes applications from all qualified candidates.
Epidemic infectious diseases pose grave risk and burden to our medical service and public health systems of the Guangdong-Hong Kong-Macao Greater Bay Area of China. These infectious disease outbreaks cause significant morbidity, mortality, socioeconomic disruption and damage to the image of good governance.
Proactive and effective “surveillance and control” of these outbreaks relies on the comprehensive knowledge of the viruses circulating in animals and human, reliable prediction of the potential of these animal viruses to jump interspecies barrier from animal to human, highly-multiplex diagnostic tests for rapid detection of these viruses in healthcare and field setting, broad spectrum antivirals for prophylactic and therapeutic treatment, and most importantly, a safe and towards-universal vaccine platform with heterologous protection against antigenically drifted viruses. The Centre for Virology, Vaccinology and Therapeutics (CVVT) is set to provide these conditions.